SOPHiA GENETICS SA (SOPH)

NASDAQ: SOPH · Real-Time Price · USD
2.989
-0.011 (-0.37%)
May 8, 2025, 4:00 PM - Market closed
-0.37%
Market Cap 199.76M
Revenue (ttm) 67.17M
Net Income (ttm) -66.17M
Shares Out 66.83M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,660
Open 3.000
Previous Close 3.000
Day's Range 2.960 - 3.050
52-Week Range 2.580 - 6.280
Beta 1.03
Analysts Strong Buy
Price Target 6.50 (+117.46%)
Earnings Date May 6, 2025

About SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North Americ... [Read more]

Sector Healthcare
IPO Date Jul 23, 2021
Employees 423
Stock Exchange NASDAQ
Ticker Symbol SOPH
Full Company Profile

Financial Performance

In 2024, SOPHiA GENETICS's revenue was $65.17 million, an increase of 4.49% compared to the previous year's $62.37 million. Losses were -$62.49 million, -20.88% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 117.46% from the latest price.

Price Target
$6.5
(117.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

SOPHiA GENETICS Reports First Quarter 2025 Results

BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the...

2 days ago - PRNewsWire

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced t...

Other symbols: AZN
10 days ago - PRNewsWire

SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its...

16 days ago - PRNewsWire

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md.

4 weeks ago - PRNewsWire

SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC

BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone:...

7 weeks ago - PRNewsWire

SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Execut...

2 months ago - Seeking Alpha

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for i...

2 months ago - PRNewsWire

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer ...

Other symbols: AZN
2 months ago - PRNewsWire

SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025

BOSTON and ROLLE, Switzerland , Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its ...

2 months ago - PRNewsWire

SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities

The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland , Jan. 28, 2025 /PRNewswire/ -- SOPHiA GEN...

3 months ago - PRNewsWire

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-n...

6 months ago - PRNewsWire

SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript

SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder ...

6 months ago - Seeking Alpha

SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previo...

6 months ago - PRNewsWire

SOPHiA GENETICS Reports Third Quarter 2024 Results

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software c...

6 months ago - PRNewsWire

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024

BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its ...

7 months ago - PRNewsWire

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzer...

8 months ago - PRNewsWire

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SO...

8 months ago - PRNewsWire

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a clou...

8 months ago - PRNewsWire

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nas...

Other symbols: AZN
8 months ago - PRNewsWire

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , ...

8 months ago - PRNewsWire

SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024

New generation of SOPHiA DDM TM  integrates latest  advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland , Sept. 4,...

8 months ago - PRNewsWire

SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference

BOSTON and ROLLE, Switzerland , Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Mo...

9 months ago - PRNewsWire

SOPHiA DDM™ Platform Certified Under IVDR

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-nativ...

9 months ago - PRNewsWire

SOPHiA GENETICS Reports Second Quarter 2024 Results

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a ...

9 months ago - PRNewsWire

SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a clou...

10 months ago - PRNewsWire